Neurology | Phase III Developments | JAPAN

Eisai

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Eisai Presents the Latest Data from the Phase 2b Open-Label Extension Study of BAN2401 at AAIC 2020

Lead Product(s): Ban2401

Therapeutic Area: Neurology Product Name: BAN2401

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Biogen

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 30, 2020

Details:

The clinical study design of the newly initiated Phase III clinical study evaluating BAN2401 for preclinical Alzheimer’s disease (AD) patients will be presented orally.

Eisai

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Eisai to Present Latest Data on Pipeline Assets In the Area of Alzheimer’s Disease and Dementia at The AAIC 2020 Conference

Lead Product(s): Ban2401

Therapeutic Area: Neurology Product Name: BAN2401

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 22, 2020

Details:

The safety and efficacy results from a Phase II clinical study on lemborexant (orexin receptor antagonist) targeting Irregular Sleep Wake Rhythm Disorder (ISWRD) associated with AD will be presented.

Chugai Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Positive Results from the Second Phase III SAkuraStar Study for Chugai’s Satralizumab in Neuromyelitis Optica Spectrum Disorder

Lead Product(s): Satralizumab

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 24, 2020

Details:

Satralizumab monotherapy significantly reduced risk of relapse in patients with NMOSD, following a previous positive study where satralizumab was added to baseline immunosuppressant therapy.

Chugai Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Chugai’s Huntington's disease drug, RG6042 gets Japanese orphan drug designation

Lead Product(s): Onis-Httrx

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 18, 2020

Details:

The company is running a clinical study in cooperation with Roche to deliver RG6042 to patients with Huntington's disease, as the first disease-modifying drug.

Kissei Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Kissei announces the publication of the results of phase III clinical trials of rovatirelin for the treatment of spinocerebellar degeneratio...

Lead Product(s): Rovatirelin

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 22, 2020

Details:

In this paper, to review the results of both phase III clinical trials, a pooled (post hoc) analysis was performed with patients who met the inclusion criteria for the additional phase III trial

Find

Find Neurology Drugs in Phase III Clinical Development in JAPAN

Japan

Product Type

Companies

Eisai

Eisai Presents the Latest Data from the Phase 2b Open-Label Extension Study of BAN2401 at AAIC 2020

Eisai

Eisai to Present Latest Data on Pipeline Assets In the Area of Alzheimer’s Disease and Dementia at The AAIC 2020 Conference

Chugai Pharmaceutical

Positive Results from the Second Phase III SAkuraStar Study for Chugai’s Satralizumab in Neuromyelitis Optica Spectrum Disorder

Chugai Pharmaceutical

Chugai’s Huntington's disease drug, RG6042 gets Japanese orphan drug designation

Kissei Pharmaceutical

Kissei announces the publication of the results of phase III clinical trials of rovatirelin for the treatment of spinocerebellar degeneratio...